| abstract |
This invention relates to methods and compositions for the treatment of sepsis, inflammation or infection. In particular, the invention concerns the use of molecule(s) that target SR-BI, which is also referred to as CLA-1 (SR-BI/CLA-1), to treat sepsis, bacterial and viral infections, and inflammatory diseases. SRB I/CLA- 1 ligands contributing to the pathogenesis of disease include LPS, LTA, viral envelope proteins, beta-amyloid, serum Amyloid A and/or heat shock proteins. |